Pharmacogenetics: From Bench Science to the Bedside
- PDF / 101,820 Bytes
- 11 Pages / 612 x 792 pts (letter) Page_size
- 33 Downloads / 229 Views
Ted Shih, PharmD GSK/UNC Drug Development Fellow, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill Manoli Vourvahis, PharmD GSK/UNC Drug Development Fellow, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill Madhu Singh, MD GSK/TJU Health Outcomes Fellow, Department of Health Policy, Thomas Jefferson University, Philadelphia, Pennsylvania Julie Papay, PharmD Manager, Toxicity Safety Evaluation and Risk Management, Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Research Triangle Park, North Carolina Key Words Pharmacogenetics; Pharmacogenomics; Individualized medicine Correspondence Address Julie Papay, PharmD, Global Clinical Safety and Pharmacovigilance, PO Box 13398, 5 Moore Drive, Research Triangle Park, NC 27709-3398 (email: [email protected]). The Drug Information Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Drug Information Association designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. If you would like to receive a statement of credit, you must review the article and complete the posttest and evaluation included on the DIA website. Participants must receive a passing score of 80% or better on the posttest in order to receive a statement of credit. To access the posttest and evaluation, please visit the DIA website at www.diahome.org, select Educational Offerings, and then select Continuing Education from the drop-down menu, and the My Transcript
503
Pharmacogenetics: From Bench Science to the Bedside Pharmacogenetics has received considerable attention in recent medical news. Extensive research has been conducted to better understand how an individual patient may respond to and benefit from a particular drug. The clinical application of pharmacogenetics, like other medical advances, requires scientific val-
idation and established clinical utility for widespread use among patients, prescribers, and payers. This activity reviews factors that contribute to the successful integration of pharmacogenetics in clinical practice, from the drug development process all the way to the patient.
Learning Objectives Upon completion of this activity, participants should be able to: • Discuss factors that contribute to the successful integration of pharmacogenetics in clinical practice. • Describe the challenges that have prevented more widespread adoption of pharmacogenetic tests in the clinical setting. • Identify the role of pharmacogenetics as a useful and cost-effective tool, from the drug development process all the way to the patient. • List specific examples of clinical utility among the available pharmacogenetic tests. Target Audience This CME activity is intended primarily for physicians, pharmacists, case managers, nurses, and other clin
Data Loading...
